


# THE CRITICAL ROLE OF B CELLS IN SJÖGREN'S DISEASE<sup>1-4</sup>

Sjögren's disease (SjD) is believed to be a B-cell-driven autoimmune disease in which hyperactivation of B cells can lead to chronic inflammation and potential irreversible organ damage. Systemic manifestations, if left untreated, may significantly impact long-term health and reduce life expectancy.<sup>1-6</sup>



# Sjögren’s disease is a serious, systemic autoimmune disease that can be progressive<sup>15-18</sup>

Beyond sicca, inflammation or damage  
can also occur in<sup>11,19,20</sup>



Joints



Skin



Lungs



Lymph nodes



Salivary glands

A more comprehensive approach to patient care is needed—one that considers not just dryness, but also other factors such as fatigue, joint pain, organ involvement, and overall disease activity<sup>16</sup>

97% of patients report  
wanting more treatment  
options<sup>21\*</sup>



Novartis has expanded its commitment to rheumatology by partnering with experts and universities to explore new ways to target B-cell hyperactivity and BAFF.

\*Based on the “Living with SjD” survey assessing demographics, symptoms, quality of life, cost, and treatment in adult patients with SjD (N=2961), which includes respondents who “somewhat agreed” or “strongly agreed.”<sup>21</sup>

**References:** **1.** Meng Q, Ma J, Cui J, Gu Y, Shan Y. Subpopulation dynamics of T and B lymphocytes in Sjögren's syndrome: implications for disease activity and treatment. *Front Immunol.* 2024;15:1468469. doi:10.3389/fimmu.2024.1468469 **2.** Du W, Han M, Zhu X, et al. The multiple roles of B cells in the pathogenesis of Sjögren's syndrome. *Front Immunol.* 2021;12:684999. doi:10.3389/fimmu.2021.684999 **3.** Ibrahem HM. B cell dysregulation in primary Sjögren's syndrome: a review. *Jpn Dent Sci Rev.* 2019;55(1):139-144. **4.** Kroese F, Abdulahad WH, Haacke E, Bos NA, Vissink A, Bootsma H. B-cell hyperactivity in primary Sjögren's syndrome. *Expert Rev Clin Immunol.* 2014;10(4):483-499. **5.** Ma D, Feng Y, Lin X. Immune and non-immune mediators in the fibrosis pathogenesis of salivary gland in Sjögren's syndrome. *Front Immunol.* 2024;15:1421436. doi:10.3389/fimmu.2024.1421436 **6.** Brito-Zerón P, Flores-Chávez A, Horváth IF, et al. Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study. *eClinicalMedicine.* 2023;61:102062. doi:10.1016/j.eclim.2023.102062 **7.** Parisi D, Chivasso C, Perret J, Soyfoo MS, Delporte C. Current state of knowledge on primary Sjögren's syndrome, an autoimmune exocrinopathy. *J Clin Med.* 2020;9(7):2299. **8.** Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren's syndrome. *Nat Rev Rheumatol.* 2013;9(9):544-556. **9.** Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjögren syndrome. *Nat Rev Rheumatol.* 2018;14:133-145. **10.** Chivasso C, Sarrand J, Perret J, Delporte C, Soyfoo MS. The involvement of innate and adaptive immunity in the initiation and perpetuation of Sjögren's syndrome. *Int J Mol Sci.* 2021;22(2):658. **11.** Negrini S, Emmi G, Greco M, et al. Sjögren's syndrome: a systemic autoimmune disease. *Clin Exp Med.* 2022;22(1):9-25. **12.** Quartuccio L, Salvin S, Fabris M, et al. BLYS upregulation in Sjögren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. *Rheumatology (Oxford).* 2013;52(2):276-281. **13.** Ridgeway D, Thalayasingam N, Ng WF. Sjögren's syndrome: shedding light on emerging and key drug targets. *Expert Opin Ther Target.* 2022;26(10):869-882. **14.** Witas R, Gupta S, Nguyen CQ. Contributions of major cell populations to Sjögren's syndrome. *J Clin Med.* 2020;9(9):3057. **15.** Brito-Zerón P, Baldini C, Bootsma H, et al. Sjögren syndrome. *Nat Rev Dis Primers.* 2016;2:16047. doi:10.1038/nrdp.2016.47 **16.** Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. *Ann Rheum Dis.* 2020;79:3-18. **17.** Thalayasingam N, Baldwin K, Judd C, Ng WF. New developments in Sjögren's syndrome. *Rheumatology (Oxford).* 2021;60(suppl 6):vi53-vi61. **18.** Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. *Arch Intern Med.* 2004;164(12):1275-1284. **19.** Vitali C, Minniti A, Pignataro F, Maglione W, Del Papa N. Management of Sjögren's syndrome: present issues and future perspectives. *Front Med (Lausanne).* 2021;8:676885. doi:10.3389/fmed.2021.676885 **20.** Mariette X, Criswell LA. Primary Sjögren's syndrome. *N Engl J Med.* 2018;378(10):931-939. **21.** McCoy SS, Woodham M, Bunya VY, et al. A comprehensive overview of living with Sjögren's: results of a National Sjögren's Foundation survey. *Clin Rheumatol.* 2022;41(7):2071-2078.